Barcelona, ​​Spain, October 13, 2020 / PRNewswire / – Almirall, SA (ALM) announced today that he signed an agreement with the French authorities to make the ILUMETRI biological treatment® (tildrakizumab), a high affinity IL-23p19 monoclonal antibody, available in France for the treatment of adult patients with severe plaque psoriasis who are candidates for systemic biologic therapy.

The agreement was signed after the Transparency Committee of High Authority of Health (HAS), the National Health Authority, gave a favorable opinion for reimbursement in France by ILUMETRI® (tildrakizumab) on June 3 and considered the actual service (Service Médical Rendu or SMR) as “significant”. The prevalence of chronic plaque psoriasis in the French population is about 5.6%.

Following the publication of the agreement in the Official Journal, Ilumetri® (tildrakizumab) will be added to the list of drugs reimbursable by social insurance for the treatment of adults with severe chronic plaque psoriasis.

“Today’s announcement is great news for patients with severe psoriasis across France who can count on safe and convenient biological treatment for their condition. Ilumetri® offers high and long-lasting efficacy and safety, and improves the quality of life of patients “ noted Alfredo Barón, Commercial Director of Almirall. “We are pleased to have been able to work with the French authorities to find an agreement to provide sustainable access to an additional biological treatment option for patients suffering from this skin disease through a national reimbursement agreement”, he added.

Ilumetri® (tildrakizumab) is the first biologic marketed by Almirall and represents an important breakthrough in the treatment of moderate to severe chronic plaque psoriasis. Since its approval by the European Commission in November 2018, the product offers a decisive advantage to patients as it has the longest efficacy and safety data among IL23p19. Ilumetri is reimbursed in 10 countries around Europe, including recent agreements in Belgium and Italy.

Tildrakizumab is administered by subcutaneous injection. Its dosage regimen, with a lower frequency of injections, only 4 injections per year during maintenance1, provides convenience and quality of life for patients, potentially improving treatment satisfaction and adherence.

The references

  1. ILUMETRI® Summary of Product Characteristics

SOURCE Almirall, SA (ALM)


Source link

About The Author

Related Posts

Leave a Reply

Your email address will not be published.